A major healthcare investment firm has become a top shareholder
Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Master LP has become a top shareholder with a 19.7% stake. At last glance, the stock was up 8.5% at $7.63, after cooling from its Aug. 7, 52-week high. The reason for Monday's peak -- positive trial data from a late-stage study of its social anxiety treatment fasedienol -- is still in focus as well.
Vistagen Therapeutics will also announce its fiscal first-quarter earnings results after the close today. The stock has moved lower following five of its last eight reports, including a large 28.7% drop in February. The options pits are pricing in a hefty 40.8% swing this time around, quadrupling the 9.7% next-day move the stock has averaged over the last two years.
VTGN's typically quiet options pits are bursting with activity straight out of the gate this morning, with options volume running at seven times the intraday average. The September 3 put is the most active contract, with new positions being bought to open there.